Overview
Aggressive primary cutaneous T-cell lymphoma (PCTCL) refers to a group of rare non-Hodgkin lymphomas that originate in the skin from mature T-lymphocytes and follow a clinically aggressive course. This category encompasses several subtypes, including primary cutaneous gamma-delta T-cell lymphoma, primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma, and primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder with aggressive features, among others. These lymphomas primarily affect the skin but can rapidly disseminate to lymph nodes, visceral organs, and bone marrow. Patients typically present with rapidly growing skin nodules, tumors, or ulcerated plaques that may be widespread at diagnosis. Systemic symptoms such as fever, weight loss, and fatigue (B symptoms) are common. The aggressive subtypes of PCTCL carry a significantly worse prognosis compared to indolent forms such as mycosis fungoides. Hemophagocytic syndrome may complicate certain subtypes, particularly gamma-delta T-cell lymphoma, and is associated with very poor outcomes. The skin lesions may be accompanied by subcutaneous involvement, necrosis, and panniculitis-like features depending on the specific subtype. Treatment of aggressive PCTCL is challenging and typically requires systemic multi-agent chemotherapy, often with regimens used for peripheral T-cell lymphomas (such as CHOP-based protocols). Allogeneic hematopoietic stem cell transplantation may be considered in eligible patients who achieve remission. Radiation therapy can be used for localized disease or palliation. Novel agents including brentuximab vedotin, romidepsin, pralatrexate, and immune checkpoint inhibitors are being investigated or used in refractory cases. Despite treatment, outcomes remain poor for most aggressive subtypes, with median survival often less than two years.
Also known as:
Sporadic
Usually appears on its own, not inherited from a parent
Adult
Begins in adulthood (age 18 or older)
FDA & Trial Timeline
10 eventsAssistance Publique - Hôpitaux de Paris
Medical College of Wisconsin — PHASE1
Kyowa Kirin, Inc. — PHASE1
Assistance Publique - Hôpitaux de Paris — EARLY_PHASE1
Assistance Publique - Hôpitaux de Paris — PHASE3
National Cancer Institute (NCI) — PHASE1
Fondazione Italiana Linfomi - ETS
H. Lee Moffitt Cancer Center and Research Institute — PHASE1
Boston Immune Technologies and Therapeutics — PHASE1
UNC Lineberger Comprehensive Cancer Center — NA
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Aggressive primary cutaneous T-cell lymphoma.
20 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Aggressive primary cutaneous T-cell lymphoma.
Community
No community posts yet. Be the first to share your experience with Aggressive primary cutaneous T-cell lymphoma.
Start the conversation →Latest news about Aggressive primary cutaneous T-cell lymphoma
1 articlesCaregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Aggressive primary cutaneous T-cell lymphoma
What is Aggressive primary cutaneous T-cell lymphoma?
Aggressive primary cutaneous T-cell lymphoma (PCTCL) refers to a group of rare non-Hodgkin lymphomas that originate in the skin from mature T-lymphocytes and follow a clinically aggressive course. This category encompasses several subtypes, including primary cutaneous gamma-delta T-cell lymphoma, primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma, and primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder with aggressive features, among others. These lymphomas primarily affect the skin but can rapidly disseminate to lymph nodes, visceral organs, and bon
How is Aggressive primary cutaneous T-cell lymphoma inherited?
Aggressive primary cutaneous T-cell lymphoma follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Aggressive primary cutaneous T-cell lymphoma typically begin?
Typical onset of Aggressive primary cutaneous T-cell lymphoma is adult. Age of onset can vary across affected individuals.
Are there clinical trials for Aggressive primary cutaneous T-cell lymphoma?
Yes — 20 recruiting clinical trials are currently listed for Aggressive primary cutaneous T-cell lymphoma on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Aggressive primary cutaneous T-cell lymphoma?
25 specialists and care centers treating Aggressive primary cutaneous T-cell lymphoma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.